Journal
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Volume 76, Issue 1, Pages 13-35Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.critrevonc.2009.12.004
Keywords
Breast cancer angiogenesis; Antiangiogenic agents; Monoclonal antibodies; Tyrosin kinase inhibitors; Metronomic chemotherapy; Bisphosphonates; Hormonal therapy; COX-2 inhibitors
Categories
Ask authors/readers for more resources
Angiogenesis is considered one of the key mechanisms of tumour growth and survival. Therefore it represents an ideal pharmaceutical target. Many antiangiogenic agents have been developed so far in several solid tumours and also in breast cancer. Vascular endothelial growth factor (VEFG) is the main target and both monoclonal antibodies and small molecules belonging to the tyrosine kinase inhibitors directed against VEGF(R) have been developed. Some other therapeutic approaches have shown to exert some antiangiogenic activity, such as hormonal agents, metronomic chemotherapy, bisphosphonates and others. In this paper we provide an introduction of the current data supporting the angiogenesis in breast cancer and a review of the most relevant antiagiogenic therapies which have been investigated so far. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available